SecBot SecBot

REGN

REGENERON PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. NY· CIK 0000872589 Biotech & Drug Discovery
$952.40 −3.07 (−0.32%)
Nov 16 4:00 PM ET · prev $955.47
Market cap
$98.4B
Large cap
Consensus
Buy
72% Buy or better · 36 analysts
Median target
$997.00
+5% · range $812.00–1,175.00
1 year
+35.2%
from $704.31 · Nov 17
30 days
+21.8%
from $782.04
52-week range
$600.66–973.36
−2% from high · low Jun 1
Avg volume 20D
1.02M
Oct 30 spike 2.87M
Short interest
2.22M
≈2.1% of shares · +3.9%
Days to cover
2.7
at average volume
Insider net
−$46.6M
0 buyers · 9 sellers · since Oct 14
New fund stakes
3
Q3 2026 13F · 2 exits
Filing reports
38
analyzed by SecBot
SecBot read BULLISH 33 reports · 90 days
Balance 1 bearish · 12 bullish · 20 neutral oldest → newest, height = score
Avg score ·High conf. 26/33

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    9 insiders sold $46.6M.

  • InstitutionsBULLISH

    Q3 2026: 66 added (3 new), 29 trimmed or exited.

  • AnalystsBULLISH

    26 of 36 rate it Buy or better. Median target $997.00 (+5%).

  • Short sellersSTEADY

    Short interest +3.9% to 2.22M shares. 2.7 days to cover, ≈2.1% of shares.

  • TrendUPTREND

    16% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 8.

Who's buying

13F· Q3 2026
3
new positions
2
exits
FundMoveSharesValue
FIRST TRUST ADVISORS LPADD826,770$626.9M
DEUTSCHE BANK AG\ADD687,345$521.2M
NORDEA INVESTMENT MANAGEMENT ABADD600,196$450.6M
BARCLAYS PLCADD348,437$264.2M
RENAISSANCE TECHNOLOGIES LLCADD272,218$206.4M
LOS ANGELES CAPITAL MANAGEMENT LLCDOUBLED266,469$202.1M
PANAGORA ASSET MANAGEMENT INCADD239,649$181.7M
MARSHALL WACE, LLPDOUBLED213,937$162.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

36 analysts
Buy 72% rate it Buy or better
Strong Buy8Buy18Hold10Sell0Strong Sell0
12-month targets · 27 analysts

Price is inside the target range. Median implies +5%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 2, 2026Leerink Partners
MAINTAIN
MAINTAINMarket Perform
Nov 2, 2026Bernstein
MAINTAIN
MAINTAINMarket Perform
Nov 2, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Nov 2, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Nov 2, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Nov 2, 2026Guggenheim
MAINTAIN
MAINTAINBuy

Washington

Corporate Lobbying

49 lobbying filings and 3 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$46.6M
sold · 9 insiders
DateInsiderTypeValue
Nov 4, 2026
Pitofsky Jason
SVP Controller
Nov 4, 2026
EXERCISE$1.1M
Nov 4, 2026
Pitofsky Jason
SVP Controller
Nov 4, 2026
EXERCISE$952.6K
Nov 4, 2026
Pitofsky Jason
SVP Controller
Nov 4, 2026
EXERCISE$445.3K
Nov 4, 2026
Pitofsky Jason
SVP Controller
Nov 4, 2026
SELL$1.1M
Nov 4, 2026
Pitofsky Jason
SVP Controller
Nov 4, 2026
SELL$499.1K
Nov 4, 2026
Pitofsky Jason
SVP Controller
Nov 4, 2026
SELL$102.0K
Nov 4, 2026
Pitofsky Jason
SVP Controller
Nov 4, 2026
SELL$33.1K
Nov 4, 2026
Pitofsky Jason
SVP Controller
Nov 4, 2026
SELL$170.2K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
17 drugs tracked · Drug pipeline →
Recent

Short side

FINRA· Oct 30, 2026
2,217,114
shares short
+3.9%
vs prior settlement
2.7
days to cover
≈2.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 Press
Regeneron announced positive Phase 2 PINNACLE trial results for baloncibart in POTS, showing a single 450 mg dose…
Impact 5/10
Nov 12, 2026 FDA
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
Data presented today for the first time at the American Autonomic Society (AAS) annual meeting
Nov 5, 2026 SEC
Seven Regeneron insiders sold a total of $9.56M in open-market sales over the week following a strong Q3 earnings beat…
CLUSTER · Impact 2/10
Nov 4, 2026 Insider
Pitofsky Jason acquired via exercise 1,500 shares
SVP Controller @ $726.53 ($1.1M)
Nov 4, 2026 Insider
Pitofsky Jason acquired via exercise 1,478 shares
SVP Controller @ $644.54 ($952.6K)
Nov 4, 2026 Insider
Pitofsky Jason acquired via exercise 905 shares
SVP Controller @ $492.00 ($445.3K)
Congressional trades
REGN trades disclosed by members of Congress, with disclosure delay.
4 members · 5 buys / 4 sells
DateMemberType AmountDisclosed
Oct 7, 2026 Ro KhannaDHouse Spouse account · Regeneron Pharmaceuticals Inc BUY $1K–$15K Nov 5, 2026 +29d
Sep 4, 2026 Ro KhannaDHouse Spouse account · Regeneron Pharmaceuticals Inc SELL $1K–$15K Oct 7, 2026 +33d
Jul 7, 2026 Ro KhannaDHouse Child account · Regeneron Pharmaceuticals Inc BUY $1K–$15K Aug 7, 2026 +31d
May 15, 2026 Gilbert CisnerosDHouse Regeneron Pharmaceuticals Inc SELL $1K–$15K Jun 8, 2026 +24d
May 15, 2026 Ro KhannaDHouse Spouse account · Regeneron Pharmaceuticals Inc SELL $1K–$15K Jun 9, 2026 +25d
May 1, 2026 Ro KhannaDHouse Child account · Regeneron Pharmaceuticals Inc SELL $1K–$15K Jun 9, 2026 +39d
Apr 13, 2026 Ro KhannaDHouse Spouse account · Regeneron Pharmaceuticals Inc BUY $1K–$15K May 11, 2026 +28d
Mar 27, 2026 Alan ArmstrongRSenate Joint account · Regeneron Pharmaceuticals Inc BUY $1K–$15K Jul 21, 2026 +116d
Feb 12, 2026 Julia LetlowRHouse Regeneron Pharmaceuticals Inc BUY $1K–$15K Mar 12, 2026 +28d

SecBot reports

38 filings · 15 press releases · 11 bullish · 2 bearish · 1 mixed · 24 neutral
All REGN filing & press-release reports (53)